Fly News Breaks for March 28, 2016
ACAD
Mar 28, 2016 | 07:49 EDT
Leerink analyst Paul Matteis says that while the FDA Psychopharmacologic Drugs Advisory Committee's briefing documents for ACADIA's Nuplazid were "more critical" than he expected, approval with a back box warning is still the most likely outcome. Should the drug for Parkinson's disease ssychosis be approved, a back box warning seems all but certain, the analyst contends. He reiterates an Outperform rating on ACADIA.
News For ACAD From the Last 2 Days